0

Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2021-2025

  • Published: Jun 2021
  • Pages: 120
  • SKU: IRTNTR40707
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single User:

    Quick and easy buy and download option

  • Enterprise:

    Flexible option - Complimentary customization included

2500 USD

The eczema therapeutics market share is expected to increase by USD 4.29 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 9.2%.

This eczema therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers eczema therapeutics market segmentations by indication (atopic dermatitis, contact dermatitis, and other) and geography (North America, Europe, Asia, and ROW). The eczema therapeutics market report also offers information on several market vendors, including AbbVie Inc., Alliance Pharma Plc , Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc. , LEO Pharma AS, Pfizer Inc., Sanofi SA, and Viatris Inc. among others.

What will the Eczema Therapeutics Market Size be During the Forecast Period?

Eczema Therapeutics Market Size

Download the Free Report Sample to Unlock the Eczema Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Eczema Therapeutics Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The high prevalence of atopic dermatitis is notably driving the eczema therapeutics market growth, although factors such as side effects associated with corticosteroids may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the eczema therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Eczema Therapeutics Market Driver

High prevalence of atopic dermatitis is a key factor driving the global eczema therapeutics market growth. There is a high prevalence of eczema globally. Eczema can be caused due to several factors, including exposure to allergens such as peanuts, pollen, or pet dander; skin irritants such as household cleaners, some fabrics, or soaps; stress; dry skin; and infections. Such a large patient pool presents a significant opportunity for the growth of the eczema therapeutics market. The large patient cohort requires multiple visits to dermatologists and numerous medications for the treatment of eczema, which consequently drives market growth. Asia also hosts a huge patient population with atopic dermatitis, with China, India, and Japan being the top three revenue contributors to the market in the region. Developing countries such as India and China present promising market opportunities due to their large population.

Key Eczema Therapeutics Market Trend

Business strategies is a key trend impacting the global eczema therapeutics market growth. The vendors operating in the market have been implementing different strategies to expand their product portfolio, especially over the last five years, which have significantly impacted the global eczema therapeutics market. They are undergoing different business strategies such as M&A and technology partnerships to increase their market presence and the sales of their eczema product range. Such strategies may provide an opportunity for vendors to increase their profit margins. in September 2020, Kymera Therapeutics Inc. entered into a multi-program strategic collaboration with Sanofi to develop and commercialize its first-in-class protein degrader therapy targeting IRAK4 in patients with immune-inflammatory diseases, including atopic dermatitis. Such initiatives will strengthen the growth of the market in focus during the forecast period.

Key Eczema Therapeutics Market Challenge

Side effects associated with corticosteroids will be a major challenge impacting negatively the global eczema therapeutics market growth. The Corticosteroids are one of the most commonly prescribed medications for all eczema indications, including atopic dermatitis. Some of the local side effects of corticosteroids in patients with eczema may include thinning of the skin (atrophy), skin thickening (lichenification), darkening of the skin, and stretch marks (striae). In some cases, they may even trigger or worsen skin disorders such as perioral dermatitis. Some of the systemic side effects of topical corticosteroids include fluid accumulation in the legs, high blood pressure, bone damage, and Cushing's syndrome. These factors discourage the use of corticosteroids for long-term eczema treatment, resulting in low adoption among patients, which, in turn, impedes the growth of the global eczema therapeutics market.

This eczema therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global eczema therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the eczema therapeutics market during the forecast period.

Who are the Major Eczema Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • AbbVie Inc.
  • Alliance Pharma Plc 
  • Bausch Health Companies Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Encore Dermatology Inc. 
  • LEO Pharma AS
  • Pfizer Inc.
  • Sanofi SA
  • Viatris Inc.

 

This statistical study of the eczema therapeutics market encompasses successful business strategies deployed by the key vendors. The eczema therapeutics market is fragmented and the vendors are deploying growth strategies such as organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • AbbVie Inc. - The company offers eczema therapeutics under the brand name RINVOQ.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The eczema therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Eczema Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the eczema therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Eczema Therapeutics Market?

Eczema Therapeutics Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from North America during the forecast period. US is the key market for eczema therapeutics in North America. Market growth in this region will be faster than the growth of the market in regions.

The market is expected to demonstrate promising growth during the forecast period due to favorable reimbursement policies, growing partnerships of key vendors with contract research organizations in emerging markets, and high healthcare expenditure will facilitate the market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 affected all countries in North America, especially the US, in 2020. It also had a negative impact on the eczema therapeutics market in North America. As of May 27, 2021, more than 32.2 million COVID-19 cases were reported in the US. A rise in the number of COVID-19 cases in the first quarter of 2021 led to a partial lockdown in several countries, including Canada and Mexico. Thus, as per the government measures and guidelines to contain the spread of COVID-19, healthcare facilities either provided non-urgent treatments and clinical visits in a limited capacity or completely shut down operations in countries across the region. Some scheduled treatments were either delayed or postponed. Hence, the approval of drugs used to treat eczema declined slightly, which impacted the growth of the regional market in 2020 and Q1 of 2021 to some extent.

What are the Revenue-generating Indication Segments in the Eczema Therapeutics Market?

Eczema Therapeutics Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The market share growth by the atopic dermatitis segment will be significant during the forecast period. The segment is also projected to grow at the fastest rate during the forecast period due to a strong pipeline landscape, with several promising product candidates in various stages of clinical development.

Besides the above-mentioned factors, the post COVID-19 impact has brought forth a slowdown in or fast tracked the demand for the service or product. This report provides an accurate prediction of the contribution of all the segments to the growth of the eczema therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Eczema Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 9.2%

Market growth 2021-2025

$ 4.29 billion

Market structure

Fragmented

YoY growth (%)

7.80

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Germany, UK, France, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AbbVie Inc., Alliance Pharma Plc , Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc. , LEO Pharma AS, Pfizer Inc., Sanofi SA, and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Eczema Therapeutics Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive eczema therapeutics market growth during the next five years
  • Precise estimation of the eczema therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the eczema therapeutics industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of eczema therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 01: Parent market
    • Exhibit 02: Market characteristics
    • Exhibit 03: Value chain analysis: Pharmaceuticals market
  • 2.2 Value chain analysis

    3 Market Sizing

    • 3.1 Market definition
      • Exhibit 05: Market segments
    • 3.2 Market segment analysis
      • 3.3 Market size 2020
        • 3.4 Market outlook: Forecast for 2020 - 2025
          • Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
          • Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

        4 Five Forces Analysis

        • 4.1 Five forces summary
          • 4.2 Bargaining power of buyers
            • Exhibit 09: Bargaining power of buyers
            • Exhibit 10: Bargaining power of suppliers
          • 4.3 Bargaining power of suppliers
            • Exhibit 11: Threat of new entrants
          • 4.4 Threat of new entrants
            • 4.5 Threat of substitutes
              • Exhibit 12: Threat of substitutes
            • 4.6 Threat of rivalry
              • Exhibit 13: Threat of rivalry
              • Exhibit 14: Market condition - Five forces 2020
            • 4.7 Market condition

              5 Market Segmentation by Indication

              • 5.1 Market segments
                • 5.2 Comparison by Indication
                  • Exhibit 17: Atopic dermatitis - Market size and forecast 2020-2025 ($ million)
                • 5.3 Atopic dermatitis - Market size and forecast 2020-2025
                  • Exhibit 18: Atopic dermatitis - Year-over-year growth 2020-2025 (%)
                  • Exhibit 19: Contact dermatitis - Market size and forecast 2020-2025 ($ million)
                • 5.4 Contact dermatitis - Market size and forecast 2020-2025
                  • Exhibit 20: Contact dermatitis - Year-over-year growth 2020-2025 (%)
                  • Exhibit 21: Other - Market size and forecast 2020-2025 ($ million)
                • 5.5 Other - Market size and forecast 2020-2025
                  • Exhibit 22: Other - Year-over-year growth 2020-2025 (%)
                  • Exhibit 23: Market opportunity by Indication
                • 5.6 Market opportunity by Indication

                  6 Customer landscape

                  • 6.1 Customer landscape

                    7 Geographic Landscape

                    • 7.1 Geographic segmentation
                      • Exhibit 26: Geographic comparison
                    • 7.2 Geographic comparison
                      • Exhibit 27: North America - Market size and forecast 2020-2025 ($ million)
                    • 7.3 North America - Market size and forecast 2020-2025
                      • Exhibit 28: North America - Year-over-year growth 2020-2025 (%)
                      • Exhibit 29: Europe - Market size and forecast 2020-2025 ($ million)
                    • 7.4 Europe - Market size and forecast 2020-2025
                      • Exhibit 30: Europe - Year-over-year growth 2020-2025 (%)
                      • Exhibit 31: Asia - Market size and forecast 2020-2025 ($ million)
                    • 7.5 Asia - Market size and forecast 2020-2025
                      • Exhibit 32: Asia - Year-over-year growth 2020-2025 (%)
                      • Exhibit 33: ROW - Market size and forecast 2020-2025 ($ million)
                    • 7.6 ROW - Market size and forecast 2020-2025
                      • Exhibit 34: ROW - Year-over-year growth 2020-2025 (%)
                      • Exhibit 35: Key leading countries
                    • 7.7 Key leading countries
                      • 7.8 Market opportunity by geography
                        • Exhibit 36: Market opportunity by geography ($ million)

                      8 Drivers, Challenges, and Trends

                      • 8.1 Market drivers
                        • 8.2 Market challenges
                          • Exhibit 37: Impact of drivers and challenges
                        • 8.3 Market trends

                          9 Vendor Landscape

                          • 9.1 Competitive scenario
                            • Exhibit 38: Vendor landscape
                          • 9.2 Vendor landscape
                            • Exhibit 39: Landscape disruption
                          • 9.3 Landscape disruption
                            • Exhibit 40: Industry risks

                          10 Vendor Analysis

                          • 10.1 Vendors covered
                            • 10.2 Market positioning of vendors
                              • Exhibit 42: Market positioning of vendors
                              • Exhibit 43: AbbVie Inc. - Overview
                              • Exhibit 44: AbbVie Inc. - Product and service
                              • Exhibit 45: ?AbbVie Inc. - Key news
                            • 10.3 AbbVie Inc.
                              • 10.4 Alliance Pharma Plc
                                • Exhibit 50: Alliance Pharma Plc  - Key offerings
                                • Exhibit 51: Alliance Pharma Plc  - Segment focus
                                • Exhibit 52: Bausch Health Companies Inc. - Overview
                                • Exhibit 53: Bausch Health Companies Inc. - Business segments
                              • 10.5 Bausch Health Companies Inc.
                                • Exhibit 54: ???Bausch Health Companies Inc. - Key news
                                • Exhibit 55: Bausch Health Companies Inc. - Key offerings
                                • Exhibit 56: Bausch Health Companies Inc. - Segment focus
                                • Exhibit 57: Bayer AG - Overview
                                • Exhibit 58: Bayer AG - Business segments
                              • 10.6 Bayer AG
                                • Exhibit 59: ???Bayer AG - Key news
                                • Exhibit 60: Bayer AG - Key offerings
                                • Exhibit 61: Bayer AG - Segment focus
                                • Exhibit 62: Eli Lilly and Co. - Overview
                                • Exhibit 63: Eli Lilly and Co. - Business segments
                                • Exhibit 64: ???Eli Lilly and Co.  - Key news
                              • 10.7 Eli Lilly and Co.
                                • Exhibit 65: Eli Lilly and Co. - Key offerings
                                • Exhibit 66: Encore Dermatology Inc.  - Overview
                                • Exhibit 67: Encore Dermatology Inc.  - Product and service
                                • Exhibit 68: Encore Dermatology Inc.  - Key offerings
                              • 10.8 Encore Dermatology Inc.
                                • Exhibit 69: LEO Pharma AS - Overview
                                • Exhibit 70: LEO Pharma AS - Business segments
                                • Exhibit 71: ????LEO Pharma AS - Key news
                              • 10.9 LEO Pharma AS
                                • Exhibit 72: LEO Pharma AS - Key offerings
                                • Exhibit 73: LEO Pharma AS - Segment focus
                                • Exhibit 74: Pfizer Inc. - Overview
                                • Exhibit 75: Pfizer Inc. - Business segments
                                • Exhibit 76: ????Pfizer Inc. - Key news
                              • 10.10 Pfizer Inc.
                                • Exhibit 77: Pfizer Inc. - Key offerings
                                • Exhibit 78: Sanofi SA - Overview
                                • Exhibit 79: Sanofi SA - Business segments
                              • 10.11 Sanofi SA
                                • Exhibit 80: ????Sanofi SA - Key news
                                • Exhibit 81: Sanofi SA - Key offerings
                                • Exhibit 82: Sanofi SA - Segment focus
                                • Exhibit 83: Viatris Inc. - Overview
                                • Exhibit 84: Viatris Inc. - Business segments
                              • 10.12 Viatris Inc.
                                • Exhibit 85: ????Viatris Inc. - Key news
                                • Exhibit 86: Viatris Inc. - Key offerings
                                • Exhibit 87: Viatris Inc. - Segment focus

                              11 Appendix

                              • 11.1 Scope of the report
                                • Exhibit 88: Currency conversion rates for US$
                              • 11.2 Currency conversion rates for US$
                                • Exhibit 89: Research Methodology
                              • 11.3 Research methodology
                                • Exhibit 90: Validation techniques employed for market sizing
                                • Exhibit 91: Information sources
                                • Exhibit 92: List of abbreviations
                              • 11.4 List of abbreviations

                                Research Framework

                                Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

                                TechnavioINFORMATION SOURCES

                                Primary sources

                                • Manufacturers and suppliers
                                • Channel partners
                                • Industry experts
                                • Strategic decision makers

                                Secondary sources

                                • Industry journals and periodicals
                                • Government data
                                • Financial reports of key industry players
                                • Historical data
                                • Press releases
                                Technavio

                                TechnavioDATA ANALYSIS

                                Data Synthesis

                                • Collation of data
                                • Estimation of key figures
                                • Analysis of derived insights

                                Data Validation

                                • Triangulation with data models
                                • Reference against proprietary databases
                                • Corroboration with industry experts
                                Technavio

                                TechnavioREPORT WRITING

                                Qualitative

                                • Market drivers
                                • Market challenges
                                • Market trends
                                • Five forces analysis

                                Quantitative

                                • Market size and forecast
                                • Market segmentation
                                • Geographical insights
                                • Competitive landscape
                                Interested in this report?
                                Get your sample now!
                                Eczema Therapeutics Market market growth will increase by $4.29 bn during 2021-2025.
                                The eczema therapeutics market market is expected to grow at a CAGR of 9.2% during 2021-2025.
                                Technavio has segmented the eczema therapeutics market market by other 1 (atopic dermatitis, contact dermatitis, and other) ,geography (North America, Europe, Asia, and ROW) , and geographic (North America, Europe, Asia, and ROW).
                                AbbVie Inc., Alliance Pharma Plc , Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc. , LEO Pharma AS, Pfizer Inc., Sanofi SA, Viatris Inc. are a few of the key vendors in the eczema therapeutics market market.
                                North America will register the highest growth rate of 40% among the other regions. Therefore, the eczema therapeutics market market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
                                The key factors driving the eczema therapeutics market market growth are:
                                • high prevalence of atopic dermatitis
                                • Business strategies
                                The eczema therapeutics market market vendors should focus on grabbing business opportunities from the atopic dermatitis segment as it accounted for the largest market share in the base year.
                                • What are the key global market and the regional market share?
                                • What are the revenue-generating key market segments?
                                • What are the key factors driving and challenging this market’s growth?
                                • Who are the key market vendors and their growth strategies?
                                • What are the latest trends influencing the growth of this market?
                                • What are the variables influencing the market growth in the primary regions?
                                • What are the factors influencing the growth of the parent market?
                                • Off-the-shelf research reports
                                • Reports can be tailored to meet the customer's needs
                                • Trusted by more than 100 fortune 500 organizations
                                • Information about the market's key drivers, trends, and challenges
                                • Parent market analysis
                                • Every week, 50,000 people visit our subscription platform
                                • Detailed vendors report with competitive landscape
                                • Covid-19 impact and recovery analysis
                                • Data on revenue-generating market segments
                                • Details on the market shares of various regions
                                • Five-force market analysis

                                Certified ISO 9001 : 2015

                                We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

                                We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

                                Safe and Secure SSL Encrypted
                                Technavio

                                info
                                close
                                • Single User:

                                  Quick and easy buy and download option

                                • Enterprise:

                                  Flexible option - Complimentary customization included

                                2500 USD

                                Technavio Get the report (PDF) sent to your email within minutes.

                                Subscribe & Save

                                Get lifetime access to our
                                Technavio Insights

                                Customized Report as per your Business Needs

                                • Our analysts will work directly with you and understand your needs
                                • Get data on specified regions or segments, competitor and Vendors
                                • Data will be formatted and presented as per your requirements
                                • We offer $1000 worth of FREE customization at the time of purchase

                                Let us help you make report more suited to your requirements.

                                • Get a competitive breakdown as per your niche industry
                                • Customize the data with various metrics that meet your business prerequisite
                                • Understand Revenue Sources, Customers and many more
                                • Details on Market Share
                                • These customizations are done in a short amount of time by our analysts and industry experts
                                Technavio
                                Enquire Before Buying
                                17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>